THERAPEUTICSMD INC (TXMD)
US88338N2062 - Common Stock
We assign a fundamental rating of 3 out of 10 to TXMD. TXMD was compared to 198 industry peers in the Pharmaceuticals industry. While TXMD seems to be doing ok healthwise, there are quite some concerns on its profitability. TXMD is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TXMD has reported negative net income.
In the past year TXMD has reported a negative cash flow from operations.
In the past 5 years TXMD reported 4 times negative net income.
In the past 5 years TXMD always reported negative operating cash flow.
1.2 Ratios
TXMD's Return On Assets of -23.72% is in line compared to the rest of the industry. TXMD outperforms 60.00% of its industry peers.
Looking at the Return On Equity, with a value of -35.08%, TXMD is in the better half of the industry, outperforming 64.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.72% | ||
| ROE | -35.08% | ||
| ROIC | N/A |
ROA(3y)-0.57%
ROA(5y)-33.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of TXMD (100.00%) is better than 100.00% of its industry peers.
In the last couple of years the Gross Margin of TXMD has grown nicely.
The Profit Margin and Operating Margin are not available for TXMD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 100% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.88%
GM growth 5Y3.8%
2. Health
2.1 Basic Checks
TXMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TXMD has more shares outstanding
Compared to 5 years ago, TXMD has more shares outstanding
There is no outstanding debt for TXMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
TXMD has an Altman-Z score of -30.25. This is a bad value and indicates that TXMD is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -30.25, TXMD is not doing good in the industry: 91.28% of the companies in the same industry are doing better.
TXMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -30.25 |
ROIC/WACCN/A
WACC9.27%
2.3 Liquidity
A Current Ratio of 1.72 indicates that TXMD should not have too much problems paying its short term obligations.
TXMD has a worse Current ratio (1.72) than 70.26% of its industry peers.
A Quick Ratio of 1.72 indicates that TXMD should not have too much problems paying its short term obligations.
TXMD has a Quick ratio of 1.72. This is in the lower half of the industry: TXMD underperforms 64.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.72 |
3. Growth
3.1 Past
TXMD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -108.03%.
TXMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -48.55%.
TXMD shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -39.53% yearly.
EPS 1Y (TTM)-108.03%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-100.85%
Revenue 1Y (TTM)-48.55%
Revenue growth 3Y-72.82%
Revenue growth 5Y-39.53%
Revenue growth Q2Q-56.35%
3.2 Future
The Earnings Per Share is expected to grow by 20.36% on average over the next years. This is a very strong growth
TXMD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.13% yearly.
EPS Next Y192.11%
EPS Next 2Y70.91%
EPS Next 3Y34.76%
EPS Next 5Y20.36%
Revenue Next Year350%
Revenue Next 2Y113.31%
Revenue Next 3Y66.91%
Revenue Next 5Y37.14%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TXMD. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 5.28 indicates a rather cheap valuation of TXMD.
Based on the Price/Forward Earnings ratio, TXMD is valued cheaper than 98.46% of the companies in the same industry.
TXMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 20.92, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.28 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TXMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TXMD's earnings are expected to grow with 34.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y70.91%
EPS Next 3Y34.76%
5. Dividend
5.1 Amount
No dividends for TXMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
THERAPEUTICSMD INC
NASDAQ:TXMD (5/1/2024, 7:27:25 PM)
1.885
+0.01 (+0.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap21.73M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.28 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.72% | ||
| ROE | -35.08% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 100% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.72 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-108.03%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y192.11%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-48.55%
Revenue growth 3Y-72.82%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y